KOSPIBiotech & Pharma317450

Myungin Pharm

₩42,050▼ 0.12%2026-11-18 close
Market Cap
₩613.9B
Turnover
₩300M
Volume
8.4K
Shares out.
14.6M
PER
6.7×
PBR
0.7×
EPS
₩6,239
Dividend Yield
3.58%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩1,500 per share · Prices as of the 2026-11-18 close

01

Report overview

Myungin Pharm: CNS-Led Growth and Margin Watch

On a CNS-focused sales base, quarterly revenue has risen for three straight quarters since the first quarter of 2026, while the 2025 operating margin fell from the prior year.

  1. 1

    Concentrated CNS franchise: 2025 standalone prescription CNS sales reached KRW 193.6 billion, or 67.39% of product sales.

  2. 2

    Revenue up, operating profit flat: sales rose from KRW 269.4 billion in 2024 to KRW 287.3 billion in 2025 (up 6.6%), while operating profit moved from KRW 92.8 billion to KRW 92.5 billion (down 0.3%).

  3. 3

    2026 quarterly trend: revenue rose to KRW 72.1 billion in Q1, KRW 76.1 billion in Q2 and KRW 76.8 billion in Q3, three straight quarterly gains. Operating profit fell 2.0% quarter on quarter to KRW 27.1 billion in Q3.

  4. 4

    Quarterly swings in net profit to controlling shareholders: KRW 23.3 billion in Q4 2025, KRW 22.7 billion in Q1 2026, KRW 24.3 billion in Q2 and KRW 21.2 billion in Q3, a 12.8% drop in Q3. The last four quarters total KRW 91.5 billion.

  5. 5

    The next checkpoints are the target completion of the pellet-dedicated plant in 2027 and the progress of the schizophrenia candidate in Phase 3.

02

Business structure

Myungin Pharm is a pharmaceutical company specializing in central nervous system (CNS) therapies, with a portfolio centered on drugs for stroke, Parkinson's disease, schizophrenia and depression. Press reports put pharmaceutical products at 99% of total sales.

In 2025 on a standalone basis, prescription CNS drugs generated KRW 193.6 billion, or 67.39% of product sales, while CNS products sold as merchandise contributed KRW 33.3 billion, or 11.61%. Over-the-counter sales included dental and oral agents at KRW 24.2 billion and digestive agents at KRW 15.8 billion.

Its flagship consumer brands are Igatan and Maykin Q. The company says it ranked first in the Korean CNS drug market by IQVIA data for Q4 2025. Reported CNS shares differ by definition: one report puts the first-half 2026 CNS share at about 67%, while another uses 78.9% for the same business.

Production is split between the Paltan No. 1 plant for tablets and the Balan No. 2 plant for active ingredients, which ran at 100.54% and 119.89% utilization in 2025. Sales depend mainly on prescriptions at hospitals and clinics. Revenue concentration in a few drug classes is both a structural feature and a risk.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3———
2025Q4₩72.1B₩23.7B32.8%
2026Q1₩72.1B₩25.1B34.8%
2026Q2₩76.1B₩27.6B36.3%
2026Q3₩76.8B₩27.1B35.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2024₩269.4B₩92.8B₩68.7B34.4%12.9%9.4%
2025₩287.3B₩92.5B₩81.4B32.2%10.3%6.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On a disclosed basis, annual revenue rose from KRW 269.4 billion in 2024 to KRW 287.3 billion in 2025, up 6.6%. Over the same period operating profit moved from KRW 92.8 billion to KRW 92.5 billion, down 0.3%, and the operating margin fell from 34.4% to 32.2%.

Net profit attributable to controlling shareholders rose 18.6%, from KRW 68.7 billion to KRW 81.4 billion. Net income including non-controlling interests moved in the same direction, from KRW 68.7 billion to KRW 81.4 billion.

Press coverage attributes the gap between the flat operating profit and the higher net income partly to one-off costs tied to the IPO preparation, and says that excluding them profitability held near the prior year's level. Operating cash flow eased from KRW 83 billion to KRW 81.6 billion.

At the end of 2025, total liabilities were KRW 47.3 billion, the debt ratio fell from 9.4% to 6.0%, and total equity of KRW 794.4 billion was entirely attributable to controlling shareholders.

Quarterly revenue bottomed at KRW 72.1 billion in Q4 2025, then rose to KRW 72.1 billion in Q1 2026, KRW 76.1 billion in Q2 and KRW 76.8 billion in Q3.

Operating profit was KRW 23.7 billion in Q4 2025, KRW 25.1 billion in Q1 2026 (up 6.1% quarter on quarter), KRW 27.6 billion in Q2 (up 10.0%) and KRW 27.1 billion in Q3 (down 2.0%). Annual R&D spending was KRW 17.7 billion in 2025, or 6.2% of sales, and Q1 2026 R&D was KRW 3.7 billion, or 5.2% of sales.

05

Industry analysis

Demand for CNS therapies is rising, driven by an aging population and greater awareness of mental health. The company itself describes steady growth in demand for CNS medicines as awareness of mental health and aging both increase.

Press analysis also links an expanding elderly population and rising medical spending to growth in the senior care market. By IQVIA data, the company's share of the Korean CNS drug market rose from 5.38% in 2022 to 6.20% in Q1 2025, and it ranked first in Q4 2025.

Industry coverage notes that the six companies with more than KRW 100 billion in annual CNS sales have mostly kept growing. Operating margins were above 33% in each year from 2020 to 2024 according to the IPO filing, which places the company near the top of the industry.

In pellet formulations, press reports at the time of the IPO put the domestic pellet drug market at about KRW 350 billion, with most supply imported from India and China. The company aims to build share through domestic production. These pellet market figures come from 2025 IPO-era coverage and may not reflect current market data.

06

Outlook

Whether the company can exceed KRW 300 billion in 2026 revenue is a main focus of press coverage. One report calculated that Q4 sales of KRW 74.8 billion would be enough to pass KRW 300 billion for the year, a level below the Q2 and Q3 results.

Press also raised the possibility of operating profit reaching KRW 100 billion. These are press calculations, not company targets. The company is pursuing a KRW 100 billion pellet plant investment, targeting completion in 2027 with annual capacity of 600 million capsules and 250 million pellet capsules.

An expansion of the Balan No. 2 plant is also under way to strengthen pellet and sustained-release capacity. On the pipeline side, a schizophrenia candidate is in global Phase 3, and the company agreed to recruit 10% of global patients in Korea and bear the cost of that trial. The Korean Phase 3 is run by the company.

The company said that if the schedule holds, the drug could launch in Korea in 2027, with sales from late 2027 into early 2028. That timeline dates from the 2025 IPO period and may shift with trial progress.

At the March 2026 general meeting, executive directors Lee Kwan-soon and Cha Bong-kwon were elected, extending the shift to professional management.

07

Valuation

PER
6.7×
PBR
0.7×
ROE
11.4%
EPS
₩6,239
BPS
₩56,967
Dividend per share
₩1,500

As of November 18, 2026, the share price sits below the company's book net asset value. Its earnings multiple can be read against the valuation used at the IPO. At listing, the company applied EV/EBITDA rather than PER and set a high discount rate of 32.2% to 47.4%.

Some argued the listing was meant to support a succession, while the company described it as a strategic step to raise its external credibility, attract talent and expand globally. Operating margins stayed above 33% in each year from 2020 to 2024 and fell to 32.2% in 2025.

On earnings, net profit to controlling shareholders over the last four quarters totals KRW 91.5 billion. Debt is small relative to equity, so the balance sheet is close to debt-free. The company introduced an interim dividend after listing, and total dividends for the year-end of 2025 were KRW 21.9 billion.

Interpreting the valuation requires weighing earnings growth, the effect of the pellet plant investment on margins, and how clinical results could change expectations.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Rising share in the CNS market

IQVIA data show the company's share of the Korean CNS drug market rising from 5.38% in 2022 to 6.20% in Q1 2025. The company says it ranked first in Q4 2025. Wider awareness of mental health and an aging population are cited as drivers of prescription growth.

High profitability and a near debt-free balance sheet

The IPO filing shows operating margins above 33% in each year from 2020 to 2024. At the end of 2025 the debt ratio was 6.0%, and total equity was fully attributable to controlling shareholders. Press reported a 34.8% operating margin for Q1 2026.

Pellet plant and drug pipeline

The company is expanding a pellet-dedicated plant targeting completion in 2027, with planned annual capacity of 600 million capsules and 250 million pellet capsules. A schizophrenia candidate is in global Phase 3, and the company runs the Korean portion. The company expects a 2027 Korean launch if the schedule holds.

09

Bear factors

Concentration in CNS drugs

Prescription CNS drugs made up 67.39% of 2025 standalone product sales. Press definitions differ, with CNS shares reported as 67% and 78.9%. Earnings that lean on one drug class are sensitive to prescribing policy changes and new competing products.

Signs of softer quarterly profit

Operating profit fell 2.0% quarter on quarter to KRW 27.1 billion in Q3 2026. Net profit to controlling shareholders fell 12.8% to KRW 21.2 billion in the same quarter. The 2025 operating margin fell to 32.2%, with the company citing partial IPO-related one-off costs.

Investment burden and governance debate

The new pellet plant is a KRW 100 billion project. At listing, the valuation method and high discount rate drew claims that the IPO aimed to support a succession, which the company rejected, citing credibility and global expansion. The pace of investment and the timing of returns could weigh on margins.

10

Risk factors

Regulation and prescribing policy

CNS prescription drugs are strongly affected by prescribing rules and drug pricing. Because most sales depend on CNS products, policy changes could affect overall results. Patent expiries or new competing products could also shift market share.

Clinical and launch timing

The company said the drug could launch in Korea in 2027 if the schedule holds. Any trial delay would push back launch and revenue timing. Because revenue is expected only from late 2027, the candidate contributes little to near-term earnings.

Capacity investment and management transition

The pellet plant is a large project costing KRW 100 billion. Depreciation and operating costs could rise during the build-out. The March 2026 general meeting changed the executive director lineup, so strategic continuity during succession matters.

11

What to watch next

  1. Early 2027

    Q4 2026 and full-year 2026 preliminary results. The 2025 full-year results were announced on March 10, 2026; the key checks are whether annual sales pass KRW 300 billion and the trend in operating margin.

  2. Late March 2027

    Filing of the 2026 annual business report and the annual general meeting. The 2026 meeting was held on March 26. The report will become the next audited annual disclosure, covering operating profit, net profit to controlling shareholders and the debt ratio.

  3. Mid-May 2027

    Q1 2027 quarterly report. The Q1 2026 report was covered on May 15, 2026; the checks are whether quarterly sales keep pace with a KRW 300 billion annual run rate and whether the operating margin holds.

  4. During 2027

    Completion and startup of the pellet-dedicated plant, and whether the schizophrenia candidate launches in Korea. Whether the completion and launch schedules hold will determine investment efficiency and the timing of new-drug revenue.

  5. Late July 2027

    Q2 2027 preliminary results. The Q2 2026 preliminary results were released on July 31, 2026. This is the point to check first-half operating margin and the trend in net profit to controlling shareholders.

12

Overall view

Myungin Pharm is growing sales from a CNS-centered base, and quarterly revenue has risen for three straight quarters since the start of 2026. Annual 2025 revenue rose 6.6% to KRW 287.3 billion, while operating profit slipped 0.3% to KRW 92.5 billion.

The operating margin fell to 32.2%, yet net profit to controlling shareholders rose 18.6% to KRW 81.4 billion. Supporting factors include a rising CNS market share, operating margins above 33% from 2020 to 2024, and a 6.0% debt ratio.

Offsetting factors include concentration in CNS drugs, the quarterly declines in Q3 2026 operating profit and net profit to controlling shareholders, and the cost of the pellet plant.

New-drug revenue is expected only from late 2027, so the assessment may depend more on mid-term pipeline progress than near-term earnings. The share price sits below book net asset value, but the IPO-era discount rate and succession debate should be considered alongside it.

The next checkpoints are the Q4 2026 preliminary results, the 2026 annual report, and the 2027 timing for plant completion and drug launch.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. apsk.co.kr
  2. kpanews.co.kr
  3. newsmp.com
  4. ibtomato.com
  5. datanews.co.kr
  6. m.dailypharm.com
  7. keyzard.cc
  8. kpanews.co.kr
  9. medigatenews.com
  10. dailypharm.com
  11. kormedi.com
  12. vegannews.co.kr
  13. medipharmhealth.co.kr
  14. ebn.co.kr
  15. kr.investing.com
  16. news.nate.com
  17. m.news.nate.com
  18. thebionews.net

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis